title: [Effect of propafenone hydrochloride on atrial signal-averaged ECG in patients with paroxysmal atrial fibrillation].
abstract: Oral propafenone hydrochloride effect was studied on atrial signal-averaged ECG (ASAECG) during time- and frequency-domain analysis in patients with paroxysmal atrial fibrillation (PAF) during ischemic heart disease (IHD). The study comprised 26 patients (15 female and 11 male) mean age 60.8 +/- 6.2. The dose of oral propafenone was 450 mg/day for all days. Recording of ASAECG and 24-hours Holter monitoring were made at baseline, after 10 days and after 6 weeks of propafenone therapy. Time-domain parameters were calculated for ASAECG: the root mean square voltage of the signals in the last 10, 20, 30 ms of the filtered P-wave (RMS 10, 20, 30) and total time duration of filtered P-wave (PWD) and time duration of P-wave for Frank leads X, Y, Z (XP, YP, ZP). During frequency-domain analysis of the terminal part of P-wave the following parameters were calculated in range from 40 Hz to 400 Hz: energy spectrum > -60 dB (A) and decibel drop at 4 Hz (Dd) in logarithmic scale and area ratio 20-50/0-20 Hz (Ar), magnitude ratio (MR1-7) in linear scale for a vector magnitude. Supraventricular arrhythmias were estimated quantitatively and qualitatively by Holter monitoring. The following parameters were estimated in a case of PAF recording: time of manifestation, duration, number of PAF episodes per day, mean heart rate during PAF and subjective symptoms. Moreover, comparable analysis of the following parameters: dimension of left atrial, age, sex, time duration of IHD and PAF and wall motion disturbances--hypokinesis and also left ventricular ejection fraction, mitral regurgitation was done between patients with effective and no effective of antiarrhythmic therapy. Our observation have indicated that oral propafenone therapy does not influence any statistically significant differences all time- and frequency-domain parameters of ASAECG in patients with PAF during IHD. Moreover, comparable analysis of above mentioned parameters has not showed statistically significant differences between examined patients with effective and lack of effective propafenone therapy.
authors.affiliation: Klinika Chorób Wewnetrznych Wojskowego Szpitala Klinicznego we Wrocławiu.
authors.forename: A
authors.initials: A
authors.lastname: Telichowski
authors.forename: W
authors.initials: W
authors.lastname: Banasiak
authors.forename: P
authors.initials: P
authors.lastname: Ponikowski
authors.forename: K
authors.initials: K
authors.lastname: Wiech
authors.forename: J
authors.initials: J
authors.lastname: Zebrowski
authors.forename: M
authors.initials: M
authors.lastname: Pieróg
authors.forename: D
authors.initials: D
authors.lastname: Kałka
authors.forename: W
authors.initials: W
authors.lastname: Lacheta
authors.forename: A
authors.initials: A
authors.lastname: Fuglewicz
authors.forename: W
authors.initials: W
authors.lastname: Molenda
mesh_terms: D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology*; D004452:Echocardiography; D004562:Electrocardiography / Q000187:drug effects* / Q000379:methods; D015716:Electrocardiography, Ambulatory; D005080:Exercise Test; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000150:complications; D011405:Propafenone / Q000494:pharmacology* / Q000627:therapeutic use; D013614:Tachycardia, Paroxysmal / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology*
chemical_list: D000889:Anti-Arrhythmia Agents; D011405:Propafenone